Curative Intent with TheraSphere™ Y-90 Therapy
The clinical insights presented by Prof. Boris Guiu, MD, PhD, Interventional Radiologist, highlight the role of TheraSphere™ Y-90 Therapy in expanding curative intent for patients with hepatocellular carcinoma (HCC).
Through multidisciplinary team (MDT) perspectives and real clinical cases, this session highlights TheraSphere ™ Y-90 Therapy as a versatile and proven therapy to bridge patients to resection or transplantation and improve long-term outcomes.
Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.